MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
Authors
Keywords
-
Journal
Nature Communications
Volume 7, Issue -, Pages 13701
Publisher
Springer Nature
Online
2016-12-06
DOI
10.1038/ncomms13701
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells
- (2015) Jing-Hong Chen et al. Autophagy
- ATM functions at the peroxisome to induce pexophagy in response to ROS
- (2015) Jiangwei Zhang et al. NATURE CELL BIOLOGY
- ATM kinase sustains HER2 tumorigenicity in breast cancer
- (2015) Venturina Stagni et al. Nature Communications
- TOPS: a versatile software tool for statistical analysis and visualization of combinatorial gene-gene and gene-drug interaction screens
- (2014) Markus K Muellner et al. BMC BIOINFORMATICS
- ATM regulates cell fate choice upon p53 activation by modulating mitochondrial turnover and ROS levels
- (2014) Kelly D Sullivan et al. CELL CYCLE
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- MEK1 Is Required for PTEN Membrane Recruitment, AKT Regulation, and the Maintenance of Peripheral Tolerance
- (2013) Katarina Zmajkovicova et al. MOLECULAR CELL
- The ATM protein kinase: regulating the cellular response to genotoxic stress and more
- (2013) Yosef Shiloh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems
- (2013) James E. DiCarlo et al. NUCLEIC ACIDS RESEARCH
- Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1
- (2013) D. N. Tripathi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Potential of the Synthetic Lethality Principle
- (2013) S. M. B. Nijman et al. SCIENCE
- RNA-Guided Human Genome Engineering via Cas9
- (2013) P. Mali et al. SCIENCE
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
- (2013) Alexander Drilon et al. Cancer Discovery
- The Aspergillus nidulans ATM Kinase Regulates Mitochondrial Function, Glucose Uptake and the Carbon Starvation Response
- (2013) Nadia Graciele Krohn et al. G3-Genes Genomes Genetics
- A new role for ATM
- (2012) Yasmine A. Valentin-Vega et al. Autophagy
- Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
- (2012) Ramaswamy Govindan et al. CELL
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
- (2012) Marcin Imielinski et al. CELL
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Functional drug–gene interactions in lung cancer
- (2012) Michal Smida et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Kinase-dead ATM protein causes genomic instability and early embryonic lethality in mice
- (2012) Kenta Yamamoto et al. JOURNAL OF CELL BIOLOGY
- Loss of ATM kinase activity leads to embryonic lethality in mice
- (2012) Jeremy A. Daniel et al. JOURNAL OF CELL BIOLOGY
- ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
- (2012) G. Hatzivassiliou et al. MOLECULAR CANCER THERAPEUTICS
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
- (2012) Andrew V. Biankin et al. NATURE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
- (2011) Markus K Muellner et al. Nature Chemical Biology
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
- (2011) Philip M Reaper et al. Nature Chemical Biology
- Cancer Research and the $90 Billion Metaphor
- (2011) E. Marshall SCIENCE
- The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
- (2010) V. J. Weston et al. BLOOD
- Inhibition of ATM kinase activity does not phenocopy ATM protein disruption
- (2010) Serah Choi et al. CELL CYCLE
- ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
- (2010) C. T. Williamson et al. MOLECULAR CANCER THERAPEUTICS
- A method and server for predicting damaging missense mutations
- (2010) Ivan A Adzhubei et al. NATURE METHODS
- Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo
- (2010) Jieru Meng et al. PLoS One
- ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS
- (2010) A. Alexander et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion
- (2009) S. E. Golding et al. MOLECULAR CANCER THERAPEUTICS
- The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
- (2008) Stephen D. Barrett et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
- (2008) S. D. Zabludoff et al. MOLECULAR CANCER THERAPEUTICS
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- Atm heterozygosity does not increase tumor susceptibility to ionizing radiation alone or in a p53 heterozygous background
- (2008) J H Mao et al. ONCOGENE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now